A practical reference on Salvage pathway: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-12 and is reviewed periodically as new material appears.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C11H15N2O8P | Identifies the atoms in the nucleotide |
| Molar mass | 334.22 g/mol | Calculated from the molecular formula |
| Appearance | White to off-white powder | Typical for purified solid material |
| Solubility | Water-soluble | Polar nucleotide; less soluble in nonpolar solvents |
| Common synonyms | Nicotinamide mononucleotide; beta-NMN | beta-NMN refers to the common anomeric form |
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
The biologically relevant form of NMN is generally the beta anomer, which is recognized by NMN adenylyltransferases. NMN is polar and water soluble, and it does not readily diffuse across lipid membranes without assistance. Whether intact NMN enters cells through a specific transporter remains an open question; some studies propose solute carrier family members, while other work favors extracellular dephosphorylation to nicotinamide riboside followed by uptake. This transport and compartmentalization debate affects how researchers interpret oral administration studies. The distinction between intracellular synthesis and extracellular delivery is central to current discussion.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. As an intermediate in the NAD+ salvage pathway, NMN is converted to nicotinamide adenine dinucleotide, a coenzyme central to cellular redox reactions. NAD+ also serves as a substrate for enzymes involved in DNA repair, stress responses, and metabolic regulation. The compound is therefore part of normal cellular biochemistry rather than an exclusively synthetic molecule.
Two enzymatic steps define the canonical route from nicotinamide to NAD+. Nicotinamide phosphoribosyltransferase, known as NAMPT, produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN adenylyltransferases, or NMNAT enzymes, then couple NMN with ATP to form NAD+. Whether intact NMN crosses cell membranes efficiently remains an active area of investigation; some studies propose direct transport, while others emphasize extracellular dephosphorylation to nicotinamide riboside followed by uptake. The relative contribution of each route likely depends on cell type, tissue, and experimental conditions.
The term NMN commonly refers to the beta isomer, in which the nicotinamide group is attached to the ribose through a beta-glycosidic bond. Commercial material may be supplied as the free acid or as a salt, such as a sodium salt, which affects molecular weight and water solubility. Related compounds include nicotinamide riboside and NAD+ itself, but these are distinct molecules with different formulas and cellular handling. Laboratory research often uses the beta form because it matches the naturally occurring configuration found in biological systems.
Small amounts of NMN occur in some foods, including certain vegetables, fruits, and animal products, though the quantities are generally low and variable. Human cells also synthesize NMN internally from nicotinamide and other precursors. Research interest increased after studies examined whether raising NAD+ levels affects metabolism and aging-related pathways in animals. Evidence in humans remains limited and mixed for many outcomes, and questions about effective absorption, tissue delivery, and long-term effects are still open. Regulatory status differs by country, with some markets treating NMN as a supplement ingredient and others restricting its sale.
Nearer Secret of Life." The news reached readers of The New York Times the next day; Victor K. McElheny, in researching his biography, "Watson and DNA: Making a Scientific Revolution", found a clipping of a six-paragraph New York Times article written from London and dated 16 May 1953 with the headline "Form of 'Life Unit' in Cell Is Scanned". The article ran in an early edition and was then pulled to make space for news deemed more important. (The New York Times subsequently ran a longer article on 12 June 1953). The university's undergraduate newspaper Varsity also ran its own short article on the discovery on Saturday 30 May 1953. Bragg's original announcement of the discovery at a Solvay conference on proteins in Belgium on 8 April 1953 went unreported by the British press. In a seven-page, handwritten letter to his son at a British boarding school on 19 March 1953 Crick explained his discovery, beginning the letter "My Dear Michael, Jim Watson and I have probably made a most important discovery". The letter was put up for auction at Christie's New York on 10 April 2013 with an estimate of $1 to $2 million, eventually selling for $6,059,750, the largest amount ever paid for a letter at auction. Sydney Brenner, Jack Dunitz, Dorothy Hodgkin, Leslie Orgel, and Beryl M Oughton, were some of the first people in April 1953 to see the model of the structure of DNA, constructed by Crick and Watson; at the time they were working at Oxford University's Chemistry Department.
=== Dota intellectual property ownership === Defense of the Ancients (DotA) was a landmark mod first released in 2003 that created the basis of the genre of multiplayer online battle arena (MOBA). It was originally developed by Kyle Sommer (who goes by the alias Eul) within Blizzard Entertainment's Warcraft III: Reign of Chaos via its world editor, and spawned several similar efforts, notably DotA-Allstars. While there had been several that contributed to DotA-Allstars, the project was managed primarily by Steve "Guinsoo" Feak, and later by "IceFrog". IceFrog was eventually hired by Valve in 2009, with the rights to the DotA intellectual property being sold to Valve the following year. Eul was also hired into Valve by 2010. Valve then subsequently filed trademarks towards a sequel to DotA, titled Dota 2. DotA-Allstars, LLC, a group of former contributors to the DotA-Allstars project, filed an opposing trademark in August 2010 to contest Valve's claim it owned the property rights. DotA-Allstars, LLC was eventually acquired by Blizzard to start development of Blizzard All-Stars. Blizzard took over the trademark challenge. The United States Patent & Trademark Office initially ruled in Valve's favor. By this point, Riot Games had hired Guinsoo to help develop its own MOBA, League of Legends. Feak transferred his rights to the Dota property to Riot, who in turn sold those to Blizzard. Blizzard filed a lawsuit against Valve to challenge Valve's ownership, pitting the rights assigned by Guinsoo at odds to those assigned to Valve by IceFrog and Eul.
Care of diabetes, obesity and other chronic diseases necessitates understanding the patient at the personal and social level as well as the molecular, and the physician–patient relationship can be an important therapeutic process. Apart from treating patients, many endocrinologists are involved in clinical science and medical research, teaching, and hospital management.
Sources: en.wikipedia.org
== History == In 2019, Hailey Rhode Bieber began conceptualizing a cosmetics brand and filed to trademark "Bieber Beauty". It was rejected, as her husband Justin Bieber had already trademarked the name in 2010. Bieber later launched rhode skin on June 15, 2022, alongside Lauren and Michael D. Ratner, choosing the name as a direct reference to her own middle name, Rhode, after her initial "Bieber Beauty" trademark application was rejected. Rhode was funded primarily by Bieber, with investment firm One Luxury Group as a strategic partner. Its core products at launch included the Peptide Glazing Fluid, Barrier Restore Cream and Peptide Lip Treatment. Within 11 days, Rhode had achieved $10 million in sales. One week following the launch, a fashion brand named Rhode co-founded by Purna Khatau and Phoebe Vickers filed a trademark infringement claim against Bieber, claiming her use of the name caused consumer confusion. A judge denied the motion "for a preliminary injunction without prejudice." In May 2025, Rhode announced it would be acquired by e.l.f. in a deal that consists of $800 million in cash and stock, with an additional $200 million based on future sales. The acquisition was completed in August. In April 2026, Rhode released the Rhode x The Biebers collaboration with Justin Bieber, introducing Spotwear hydrocolloid pimple patches alongside limited-edition versions of its Peptide Lip Treatment and Peptide Eye Prep.
Portugal is a high-income country with an advanced economy that follows the Mediterranean model. The country's economic policy is framed by strategic guidelines called Major Options, which are subsequently implemented through the State Budget. Portugal has the EU's 14th-largest economy by nominal GDP and the 12th-largest economy by PPP-adjusted GDP. Its PPP-adjusted GDP per capita stood at to 81% of the EU average in 2025. As of 2024, Portugal's service sector contributed the most for its economic output followed the industrial sector and its primary sector. In 2025, Portugal unemployment rate was 5.8%. As of 2024, its poverty rate after social transfers was 15.4% of the population while in 2023, the at-risk-of-poverty rate before social transfers stood at 40.3%. The national debt of Portugal was estimated at 89.2% relative to GDP as of 2025. Portugal is part of the European single market which represents more than 450 million consumers. Portugal replaced the escudo with the euro in 2002. Its monetary policy is set by the European Central Bank. The country has been a part of the Eurozone since its inception. Portugal's central bank is the Banco de Portugal and it is part of the European System of Central Banks. In 2024, Portugal had a combined share of exports and imports that amounted to 90% of its total GDP. In February 2026, Portugal's main export markets were Spain at 26% and Germany at 13.9%. Its main exports are machinery and mechanical appliances, vehicles and other transportation equipment, base metals, and plastics.
==== Suprageneric subdivisions ==== Due to the diversity of the originally broadly defined Liliaceae s.l., many attempts have been made to form suprageneric classifications, e.g. subfamilies and tribes. Classifications published since the use of molecular methods in phylogenetics have taken a narrower view of the Liliaceae (Liliaceae s.s.). The Angiosperm Phylogeny Website (APweb) recognizes three subfamilies, one of which is divided into two tribes.
Sources: en.wikipedia.org
=== Converting nucleotides to deoxynucleotides === Nucleotides are initially synthesized with ribose as the sugar component, a characteristic feature of RNA. However, DNA requires deoxyribose, which lacks the 2'-hydroxyl (-OH) group on the ribose. The removal of this -OH group is catalyzed by ribonucleotide reductase, an enzyme that converts nucleoside diphosphates (NDPs) into their deoxy forms, deoxynucleoside diphosphates (dNDPs). The nucleotides must be in the diphosphate form for this reaction to occur. To synthesize thymidine, a DNA-specific nucleotide that exists only in the deoxy form, uridine is first converted into deoxyuridine by ribonucleotide reductase. Deoxyuridine is then methylated by thymidylate synthase to produce thymidine.
== Adverse effects == Immunotherapies as a group have off-target effects and toxicities common to them. Some of these include interstitial pneumonitis, colitis, hepatitis, thyroiditis, skin reactions, low levels of platelets and white blood cells, inflammation of the brain or spinal cord, neuromuscular adverse events including myositis, Guillain–Barré syndrome, myasthenia gravis; myocarditis and cardiac insufficiency, acute adrenal insufficiency, and nephritis. The most common kidney related changes are acute interstitial nephritis, followed by glomerular diseases and then tubular damage. The detailed mechanism of these adverse effects are not fully elucidated; however, they are clearly different from known autoimmune diseases. Immune-mediated adverse reactions are usually attributed to generalised dysregulation of T cells or development of autoantibodies, although memory T cell responses against occult viral infections might also play a role in some patients with advanced melanoma following combined PD-1/CTLA-4 blockade. When compared with standard chemotherapeutic agents, PD-1/PD-L1 inhibitors had a lower reported incidence of fatigue, sensory neuropathy, diarrhea, bone marrow suppression, loss of appetite, nausea, and constipation.
== Overdose and toxicity == The German Federal Institute for Risk Assessment warns that muscimol and products containing it pose serious health risks, especially to children. The toxicity and safety profile of muscimol has been studied in various contexts, both experimental and clinical. It is described as being a relatively toxic compound in animals. The median lethal dose (LD50) in mice is 5.6 to 7 mg/kg intravenously, 3.8 mg/kg subcutaneously, 2.5 to 12 mg/kg intraperitoneally, and 22 mg orally. The LD50 in rats is 4.5 mg/kg intravenously and 45 mg/kg orally. Muscimol shows considerably greater lethal potency or toxicity than gaboxadol. A study on non-human primates indicated that muscimol, when administered in escalating doses, caused reversible hyperkinesia and dyskinesias at higher doses, but no long-term toxicity was observed on histological examination. Muscimol has shown potential as an anticonvulsant, blocking seizures induced by various agents in animal models without causing significant toxicity at therapeutic doses. Muscimol exhibits dose-dependent effects with higher doses leading to significant, but reversible, central nervous system symptoms. The dose of muscimol that is thought to be potentially fatal in humans has been reported to be approximately 90 mg, which is 15 times the reported threshold hallucinogenic dose of 6 mg.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a nucleotide intermediate in the cellular pathway that produces NAD+, a coenzyme involved in energy metabolism and signaling. NMN is not the same compound as NAD+.
NMN is a direct precursor to NAD+ in the salvage pathway. The enzyme NMNAT converts NMN into NAD+ by adding an adenine nucleotide group. This relationship is why NMN is studied in the context of NAD+ decline.
Yes, NMN is produced naturally in cells as part of NAD+ recycling. It also appears in small and variable amounts in some foods. Its natural presence does not by itself establish that supplemental NMN has clinical benefits.
NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ biosynthesis. It occurs naturally in cells and is also produced commercially as a supplement ingredient.